SABCS 2023 Insights: "Biology or Stage? Tailoring Treatment for Premenopausal Women With Nodal Involvement, but Low Genomic Prognostic Assay"

Login

Password

Forgot your password?

Join VuMedi

Select specialty

First name

Last name

Choose Password

About Us
Careers
Partner with us
F.A.Q
Contact us
Terms & conditions
Privacy policy

Playback speed

10 seconds

Video Player is loading.

Current Time 0:00

Duration 0:00

Loaded: 0%

Stream Type LIVE

Remaining Time -0:00

0.5x
0.75x
1x, selected
1.25x
1.5x
1.75x
2x

Chapters

descriptions off, selected

captions settings, opens captions settings dialog
captions off, selected

This is a modal window.

Beginning of dialog window. Escape will cancel and close the window.

TextColorTransparency

BackgroundColorTransparency

WindowColorTransparency

Font Size

Text Edge Style

Font Family

End of dialog window.

This is a modal window. This modal can be closed by pressing the Escape key or activating the close button.

SABCS 2023 Insights: "Biology or Stage? Tailoring Treatment for Premenopausal Women With Nodal Involvement, but Low Genomic Prognostic Assay"

By Insights from 2023 SABCS FEATURING Kevin Kalinsky

0 views

December 19, 2023

Comments 0

CDK4/6 Inhibitors as First-Line Treatment for HR+, HER2- MBC

Feat. J. O’Shaughnessy

Progression on First-Line Therapy in HR+, HER2- MBC: Treatments and …

Feat. J. O’Shaughnessy

ASCO® 2024 Breast Cancer Highlights - Monday Morning Practice

Feat. S. Tolaney, H. Rugo